drugset
drugset / Trial / NCT04380324

A Study of NKTR-358 (LY3471851) in Healthy Participants

NCT04380324 ↗

Phase 1 Completed 100 enrolled Nektar Therapeutics Eli Lilly and Company · collab
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this study is to evaluate the safety and tolerability of a study drug known as LY3471851 in healthy participants. The study will last about 50 days for each participant.

Timeline

Start
2017-03-19
Primary completion
2019-01-20
Completion
2019-01-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Rezpegaldesleukin Protein / enzyme biologic — Subcutaneous

Indications

No indication recorded.